Dexcel Pharma Technologies Ltd.
SEC CIK 1720007 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | 10% | 98.85M | $155.0K | — | 1 | 2022-04-22 | 2022-04-22 |
Most active insiders at ROIV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MANCHESTER KEITH S | Dir | — | $154.47M |
| 2 | Gold Daniel Allen | Dir | — | $147.38M |
| 3 | QVT Financial LP | Dir by Deputization | — | $147.38M |
| 4 | Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| 5 | Ramaswamy Vivek | 10% | — | $105.88M |
| 6 | Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| 7 | Torti Frank | Pres, Vant COB | — | $82.04M |
| 8 | Gline Matthew | CEO, Dir | — | $46.17M |
| 9 | Pulik Richard | CFO | — | $9.12M |
| 10 | Fitzgerald Meghan | Dir | — | $3.27M |
Dexcel Pharma Technologies Ltd. made no open-market trades at ROIV in the last 12 months.
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-04-26 | 2022-04-22+ | ROIV | Roivant Sciences Ltd. | Dexcel Pharma Technologies Ltd. | 10% | P - Purchase | $3.85 | +40.3K | 98.85M | +0.0% | +$155.0K |
Purchase Sale Sale after option exercise All abbreviations